Guangdong Jiaying Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Guangdong Jiaying Pharmaceutical has been growing earnings at an average annual rate of 39%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 3.3% per year. Guangdong Jiaying Pharmaceutical's return on equity is 3.6%, and it has net margins of 5.5%.
Key information
39.0%
Earnings growth rate
39.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.3% |
| Return on equity | 3.6% |
| Net Margin | 5.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Guangdong Jiaying Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 499 | 27 | 267 | 10 |
| 31 Dec 23 | 533 | 34 | 293 | 10 |
| 30 Sep 23 | 622 | 47 | 324 | 15 |
| 30 Jun 23 | 670 | 54 | 343 | 15 |
| 31 Mar 23 | 667 | 54 | 348 | 15 |
| 31 Dec 22 | 659 | 44 | 354 | 15 |
| 30 Sep 22 | 587 | 19 | 343 | 16 |
| 30 Jun 22 | 569 | 6 | 358 | 14 |
| 31 Mar 22 | 573 | -4 | 377 | 14 |
| 01 Jan 22 | 575 | 1 | 377 | 14 |
| 30 Sep 21 | 592 | 25 | 385 | 9 |
| 30 Jun 21 | 589 | 27 | 381 | 13 |
| 31 Mar 21 | 574 | 26 | 370 | 11 |
| 31 Dec 20 | 545 | 20 | 348 | 9 |
| 30 Sep 20 | 518 | -143 | 373 | 20 |
| 30 Jun 20 | 494 | -139 | 361 | 15 |
| 31 Mar 20 | 505 | -129 | 362 | 14 |
| 31 Dec 19 | 501 | -122 | 362 | 14 |
| 30 Sep 19 | 540 | 40 | 355 | 12 |
| 30 Jun 19 | 538 | 38 | 343 | 12 |
| 31 Mar 19 | 531 | 36 | 333 | 12 |
| 31 Dec 18 | 537 | 36 | 328 | 12 |
| 30 Sep 18 | 510 | -211 | 303 | 10 |
| 30 Jun 18 | 495 | -213 | 298 | 10 |
| 31 Mar 18 | 483 | -214 | 291 | 10 |
| 31 Dec 17 | 468 | -215 | 287 | 10 |
| 30 Sep 17 | 469 | 48 | 282 | 0 |
| 30 Jun 17 | 471 | 49 | 283 | 0 |
| 31 Mar 17 | 455 | 55 | 271 | 0 |
| 31 Dec 16 | 450 | 55 | 265 | 0 |
| 30 Sep 16 | 432 | 45 | 266 | 0 |
| 30 Jun 16 | 421 | 50 | 252 | 0 |
| 31 Mar 16 | 445 | 60 | 252 | 0 |
| 31 Dec 15 | 476 | 66 | 265 | 0 |
| 30 Sep 15 | 490 | 65 | 254 | 0 |
| 30 Jun 15 | 524 | 74 | 260 | 0 |
| 31 Mar 15 | 544 | 71 | 257 | 0 |
| 31 Dec 14 | 566 | 74 | 256 | 0 |
| 30 Sep 14 | 529 | 174 | 236 | 0 |
| 30 Jun 14 | 428 | 164 | 182 | 0 |
| 31 Mar 14 | 323 | 154 | 135 | 0 |
| 31 Dec 13 | 227 | 139 | 102 | 0 |
| 30 Sep 13 | 125 | 23 | 59 | 0 |
| 30 Jun 13 | 120 | 18 | 59 | 0 |
Quality Earnings: 002198 has high quality earnings.
Growing Profit Margin: 002198's current net profit margins (5.5%) are lower than last year (8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002198's earnings have grown significantly by 39% per year over the past 5 years.
Accelerating Growth: 002198's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002198 had negative earnings growth (-49%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4.8%).
Return on Equity
High ROE: 002198's Return on Equity (3.6%) is considered low.